Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

UNITEDHEALTH GROUP INC.

(UNH)
  Report
Delayed Nyse  -  04:01 2022-11-30 pm EST
547.76 USD   +3.74%
11/29Transcript : UnitedHealth Group Incorporated - Analyst/Investor Day
CI
11/29UnitedHealth Group Issues 2023 Outlook; Reiterates 2022 Adjusted Earnings Guidance
MT
11/28Unitedhealth Group Inc : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

UnitedHealth Group : The underlying trend is in force again

11/24/2022 | 02:44am EST
long trade
Live
Entry price : 534$ | Target : 590$ | Stop-loss : 498.86$ | Potential : 10.49%
Shares in UnitedHealth Group show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors have an opportunity to buy the stock and target the $ 590.
UnitedHealth Group : UnitedHealth Group : The underlying trend is in force again
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
  • UnitedHealth Group Inc. accounts for 4.65 % of our USA Portfolio. A trade is currently open since 11/02/2015 with a purchase price of $ 130.26. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.

Strengths
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company benefits from high valuations in earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.
Ratings chart
Subsector Other Managed Healthcare
1st jan.Capitalization (M$)Investor Rating
UNITEDHEALTH GROUP INC.6.00%493 336
ELEVANCE HEALTH, INC.11.18%123 082
CIGNA CORPORATION39.66%98 050
HUMANA INC.15.18%67 496
CENTENE CORPORATION2.45%47 804
MOLINA HEALTHCARE, INC.1.46%18 847
PROGYNY, INC.-27.31%3 400
ALIGNMENT HEALTHCARE, INC.-10.31%2 361
More Results

ę MarketScreener.com 2022

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2022 324 B - -
Net income 2022 20 015 M - -
Net Debt 2022 26 491 M - -
P/E ratio 2022 25,1x
Yield 2022 1,19%
Capitalization 512 B 512 B -
EV / Sales 2022 1,66x
EV / Sales 2023 1,51x
Nbr of Employees 350 000
Free-Float 99,5%
Upcoming event on UNITEDHEALTH GROUP INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 528,00 $
Average target price 580,54 $
Spread / Average Target 9,95%
EPS Revisions
Managers and Directors
Andrew Philip Witty Chief Executive Officer & Director
Dirk C. McMahon President & Chief Operating Officer
John Franklin Rex Chief Financial Officer & Executive Vice President
Stephen J. Hemsley Chairman
Margaret-Mary Wilson Chief Medical Officer & Executive Vice President